GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

London: GSK plc has announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

Hengrui’s peptide drug, HRS9531, is engineered to bind to and activate the GLP-1 and GIP receptors — the same two targets hit by blockbuster Eli Lilly’s chronic weight management drug, Zepbound.